Quantcast

Ground Breaking Findings on Understanding Cancer Published in the Current Issue of ‘Science’

October 5, 2010

GIESSEN, Germany, October 5, 2010 /PRNewswire/ –

– Biomarker ‘M2-PK’ Identified as Key Enzyme in Cancer Diagnosis and
Therapy

– Warburg hypothesis (named after the Nobel prize winner) confirmed

– Cancer cells can be recognised by their metabolism

– Scientists from Harvard Medical School in Boston report on the enzyme
‘M2-PK’ in a study in the renowned specialist journal ‘Science’

– Tests for detecting M2-PK in blood or also in stool samples are already
available

– Extremely promising new compounds target ‘M2-PK’

Cancer research is facing a radical change of direction. Cancer cells do
not obtain their energy from the breakdown of sugar to carbon dioxide and
water, but from energy-rich intermediates of sugar metabolism instead. This
confirms the hypothesis developed by the German Noble prizewinner Otto
Warburg
over 80 years ago, that an altered energy production in human
metabolism is characteristic of cancer. The key enzyme ‘M2-PK’ (PKM2) hereby
plays a decisive role, as scientists from Harvard Medical School report in
the current issue of the world-renowned specialist magazine ‘Science’.

The results of these experiments represent a significant change in
direction in the field of cancer research. They also confirm the earlier
findings of scientists such as Warburg, Eigenbrodt and Mazurek that tumour
cells express their own characteristic isoform of the glycolytic key enzyme
pyruvate kinase. M2-PK is the synonym for both the dimeric and also the
tetrameric forms of the M2 pyruvate kinase isoenzyme (also known as PKM2).
The dimeric form of M2-PK is dominant in tumour cells.

A simple commercial test is already available to measure the biomarker
M2-PK in stool and blood

M2-PK in stool samples can be used to screen for bowel (colorectal)
cancer and in blood for monitoring therapy response and patient follow-up of
various cancers. Effective and simple tests are already available for the
detection of this enzyme, which have been developed and patented by the
company ScheBo Biotech AG situated in Giessen, Germany, and are already
marketed as commercial test kits.

Biomarker M2-PK in stool samples for the screening and early detection of
bowel cancer and polyps

Clinical studies from Germany, Great Britain and Ireland, which tested
M2-PK in stool samples as a metabolic marker for the early detection of bowel
cancer, show detection rates between 78% and 97%. That means that in the
various studies between 78 and 97 people out of every 100 people with bowel
cancer are detected by the M2-PK Stool Test. For polyps >1cm the detection
rate lay at 60%; for polyps <1cm it was 25%. The sensitivity for all polyps
was 40%.

It is therefore possible to detect bowel polyps as well as bowel tumours
with high sensitivity using the biomarker ‘M2-PK’ in faecal samples, without
the need to detect blood in the stool. The result is not affected by diet or
specific foods, so a special diet is not required. There are no false
positive results from haemorrhoids or other sources of bleeding into the
bowel. The test can detect non-bleeding as well as bleeding bowel polyps or
tumours. These scientific findings represent a change in direction in the
early detection and screening for polyps and cancer of the bowel.

M2-PK in blood as a biomarker for therapy response and patient follow-up
in various cancers

Studies from research groups around the world have shown that the
concentration of M2-PK is significantly increased in the blood of patients
with renal, lung, breast,cervical and gastrointestinal (colon, rectal,
gastric [stomach], pancreatic, oesophageal) tumours, as well as melanoma, and
correlates with the severity of the disease.

The monitoring of patients receiving therapy is an important application
for the detection of M2-PK in EDTA-plasma, which assists with the early
recognition of the success or failure of a therapy and in predicting the
chances of recovery.

Newly developed compounds which target ‘M2-PK’ successfully block cancer
metabolism

ScheBo Biotech AG is not only a pharmaceutical biotech company which is
active in the development of in-vitro diagnostics, but has also already
developed extremely promising candidate compounds targeted against ‘M2-PK’
which sequentially block cancer metabolism. Significant successes in blocking
cancer cells have already been achieved in preclinical studies with these
innovative compounds. The company is extremely confident that a fundamental
breakthrough has been achieved with this new approach, according to board
members Dr. Ursula Scheefers-Borchel and Dr. Hans Scheefers.

    Source: Science 17 September 2010: Vol. 329. no. 5998, pp. 1492 - 1499;
DOI: 10.1126/science.1188015

    ScheBo(r)-Biotech AG
    Tel: +49-641-4996-0
    Fax: +49-641-4996-78
    E-Mail: info@schebo.com

http://www.schebo.com

http://www.metabolic-database.com

SOURCE ScheBo Biotech AG


Source: newswire



comments powered by Disqus